SCHEMBL4376161

SCHEMBL4376161

CC(NC(=O)Nc1ccc2[nH]c(-c3cscn3)nc2c1)c1cccc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.45
METAP1 P53582 4/20 0.45
METAP2 P50579 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
FKBP1A P62942 1/20 0.44
HIF1A Q16665 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
IDH1 O75874 1/20 0.44
PDE2A O00408 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4371839 0.94 METAP1 (0.43) TRPV1METAP1METAP2KDM4ENPC1
SCHEMBL13624141 0.93 METAP1 (0.52) TRPV1METAP1METAP2KDM4ENPC1
SCHEMBL4365319 0.87 METAP1 (0.48) METAP1METAP2KDM4ENPC1TP53
SCHEMBL4367957 0.87 METAP1 (0.48) METAP1METAP2KDM4ENPC1TP53
Trifluoroacetic Acid SCHEMBL4376103 0.82 METAP1 (0.44) METAP1METAP2KDM4ENPC1TP53
SCHEMBL13624140 0.79 METAP1 (0.56) METAP1METAP2KDM4ENPC1TP53
SCHEMBL5222448 0.79 CA12 (0.45) METAP1METAP2KDM4ENPC1TP53
SCHEMBL4375202 0.79 METAP1 (0.46) TRPV1METAP1METAP2KDM4ENPC1
SCHEMBL4366036 0.79 TACR3 (0.48) TRPV1METAP1METAP2KDM4ENPC1
SCHEMBL4368861 0.79 TACR3 (0.48) TRPV1METAP1METAP2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622592-B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-11-24 US claimed
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US claimed
US-7622592-B2 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK & CO., INC. (US) 2009-11-24 US disclosed
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators MERCK SHARP & DOHME CORP. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060036098-A1 Carbonylamino-benzimidazole derivatives as androgen receptor modulators AR, SHBG, BRCA1 TRPV1 2848/4885METAP1 3988/4885METAP2 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.